Product Description
Discovered through our unique chemoproteomic platform, IMTAC™, the TEAD inhibitor BGC515 represents a significant breakthrough. The FDA's endorsement of this IND not only validates our innovative platform but also highlights a critical step forward in our mission to develop pioneering treatments for cancer patients. (Sourced from: https://www.bridgenebio.com/news/bridgene-biosciences-announces-fda-acceptance-of-ind-application-of-novel-tead-inhibitor-bgc515)
Mechanisms of Action: TEAD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BridGene Biosciences Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BGC-515](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Epithelioid Hemangioendothelioma|Mesothelioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BGC515-101 | P1 |
Recruiting |
Epithelioid Hemangioendothelioma|Mesothelioma |
2027-06-01 |